In conclusion, our analysis of clinical NSCLC cohorts revealed that dysregulation of the EGFR/MAP2K1/mTOR/YAP1 signaling pathways was associated with the progression, therapeutic resistance, immune-invasive phenotypes, and worse prognoses of NSCLC. The gene discussed is MAP2K1; the disease is non-small cell lung carcinoma.